Latest Pirfenidone Stories
First FDA Approved Treatments in United States for Devastating Lung Disease Affecting More than 200,000 Americans, with Survival Rate of Just Three to Five Years CHICAGO, Oct.
FLINT, Mich., Oct.
-- Roche to acquire InterMune for $74.00 per share -- BASEL, Switzerland, Aug. 24, 2014 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and InterMune, Inc.
-- Transformational H1 2014 includes presentation of Phase 3 ASCEND data, NDA resubmission and target PDUFA date of Nov. 23 for pirfenidone in U.S. - BRISBANE, Calif., Aug.
SAN DIEGO, Aug. 5, 2014 /PRNewswire/ -- Genoa Pharmaceuticals, the leader in inhaled medicines for pulmonary fibrosis, today announced the U.S.
BRISBANE, Calif., July 28, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its second quarter 2014 financial results at the close of the U.S.
Nintedanib and Pirfenidone Received Breakthrough Therapy Designation by the U.S.
BRISBANE, Calif., July 17, 2014 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that pirfenidone has been granted Breakthrough Therapy Designation from the U.S.
BRISBANE, Calif., May 27, 2014 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it has resubmitted its pirfenidone New Drug Application (NDA) to the U.S.
- Pooled Efficacy Analyses from Phase 3 ASCEND and CAPACITY Studies Presented at 2014 American Thoracic Society Meeting - SAN DIEGO, May 20, 2014 /PRNewswire/ -- InterMune, Inc.
- totally perplexed and mixed up.